These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20142330)

  • 1. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
    Contreras CM; Akbay EA; Gallardo TD; Haynie JM; Sharma S; Tagao O; Bardeesy N; Takahashi M; Settleman J; Wong KK; Castrillon DH
    Dis Model Mech; 2010; 3(3-4):181-93. PubMed ID: 20142330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
    Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ
    Cancer Res; 2014 Jan; 74(1):15-23. PubMed ID: 24322983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
    Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
    PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
    Contreras CM; Gurumurthy S; Haynie JM; Shirley LJ; Akbay EA; Wingo SN; Schorge JO; Broaddus RR; Wong KK; Bardeesy N; Castrillon DH
    Cancer Res; 2008 Feb; 68(3):759-66. PubMed ID: 18245476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.
    Peña CG; Nakada Y; Saatcioglu HD; Aloisio GM; Cuevas I; Zhang S; Miller DS; Lea JS; Wong KK; DeBerardinis RJ; Amelio AL; Brekken RA; Castrillon DH
    J Clin Invest; 2015 Nov; 125(11):4063-76. PubMed ID: 26413869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
    Bajwa P; Nielsen S; Lombard JM; Rassam L; Nahar P; Rueda BR; Wilkinson JE; Miller RA; Tanwar PS
    Oncotarget; 2017 Jan; 8(5):7265-7275. PubMed ID: 27980219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of mTOR activity through LKB1 inactivation.
    Zhou W; Marcus AI; Vertino PM
    Chin J Cancer; 2013 Aug; 32(8):427-33. PubMed ID: 23668926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Chiu CW; Nozawa H; Hanahan D
    J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
    Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
    Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT.
    Yoo JY; Kang HB; Broaddus RR; Risinger JI; Choi KC; Kim TH
    BMC Cancer; 2018 May; 18(1):605. PubMed ID: 29843645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.
    Shackelford DB; Vasquez DS; Corbeil J; Wu S; Leblanc M; Wu CL; Vera DR; Shaw RJ
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11137-42. PubMed ID: 19541609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
    Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; García-Echeverría C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK
    Cancer Cell; 2010 Jun; 17(6):547-59. PubMed ID: 20541700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.
    McCampbell AS; Harris HA; Crabtree JS; Winneker RC; Walker CL; Broaddus RR
    Cancer Prev Res (Phila); 2010 Mar; 3(3):290-300. PubMed ID: 20179297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
    Zhou C; Gehrig PA; Whang YE; Boggess JF
    Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.